![](https://endpts.com/wp-content/uploads/2016/09/Twitter-Copy-1.png)
Senior FDA officials warned that approving $300,000 Duchenne drug will lower agency standards
In the end, Sarepta did many things wrong when it came to developing a new drug for Duchenne muscular dystrophy. But it got one very …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.